Compass Therapeutics, Inc. (CMPX)
(Delayed Data from NSDQ)
$1.41 USD
+0.05 (3.68%)
Updated May 31, 2024 04:00 PM ET
After-Market: $1.42 +0.01 (0.71%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CMPX 1.41 +0.05(3.68%)
Will CMPX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for CMPX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CMPX
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should Know
Compass Therapeutics, Inc. (CMPX) Loses -28.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
CMPX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CMPX
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
Compass Therapeutics Announces CEO Transition
Compass Therapeutics Announces CEO Transition and New Leadership
Compass Therapeutics names Thomas Schuetz as CEO
Compass Therapeutics CEO Vered Bisker-Leib steps down, Thomas Schuetz succeeds